Summit lung cancer drug shows 'striking' benefit over Keytruda - BioPharma Dive
Summit Therapeutics' experimental drug ivonescimab reduced lung cancer progression risk by 49% compared to Merck's Keytruda in a Phase 3 trial, with a median progression-free survival of 11 months versus 6 months for Keytruda. Ivonescimab, discovered by Akeso, targets PD-1 and VEGF, showing potential to become a new standard treatment, though further global trials are needed to confirm its superiority over Keytruda plus chemotherapy.
Related Clinical Trials
Highlighted Terms
Related News
Summit Therapeutics' experimental therapy, ivonescimab, outperformed Merck's Keytruda in a late-stage lung cancer trial, reducing tumor progression risk by 49%.
Summit Therapeutics and Akeso's Phase III HARMONi-2 trial results show ivonescimab, a bispecific monoclonal antibody, outperforming Merck's Keytruda in non-small cell lung cancer patients with PD-L1 TPS above 1%, with significant median progression-free survival and overall response rate advantages. However, safety concerns and the need for a multiregional trial may limit immediate FDA approval. GlobalData forecasts ivonescimab reaching $1.7bn in sales by 2030, challenging Keytruda's market dominance.
Summit Therapeutics' experimental drug, ivonescimab, reduced lung cancer progression risk by 49% compared to Merck's Keytruda in a Phase 3 trial, showing a 5.3-month longer median progression-free survival. The study, conducted in China, did not compare ivonescimab to Keytruda plus chemotherapy, which is standard for many cases. Summit plans further global studies to address these limitations.
Summit Therapeutics' ivonescimab outperformed Merck's Keytruda in NSCLC treatment, with data from China trials showing significant PFS benefits. Analysts caution on data generalizability, and FDA approval may require U.S. data. Ivonescimab also showed promise in other cancers, but overall survival data is pending. Summit plans multi-regional trials in 2025.
Summit Therapeutics' experimental drug ivonescimab reduced lung cancer progression risk by 49% compared to Merck's Keytruda in a Phase 3 trial, with a median progression-free survival of 11 months versus 6 months for Keytruda. Ivonescimab, discovered by Akeso, targets PD-1 and VEGF, showing potential to become a new standard treatment, though further global trials are needed to confirm its superiority over Keytruda plus chemotherapy.
Summit Therapeutics' ivonescimab reduced lung cancer progression or death risk by 49% compared to Keytruda in Phase III HARMONi-2 study, extending progression-free survival to 11 months vs. 6 months for Keytruda. The study involved 398 PD-L1-positive, advanced NSCLC patients in China, with ivonescimab showing higher severe side effects.